1. Scrip

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

 
• By Jessica Merrill

Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.

Rebates_535538281_1200.jpg

After both a phone call and a White House meeting with President Donald Trump, Pfizer Inc. CEO Ian Read was pushed during the firm’s second quarter earnings call for his thoughts on what could be on the horizon when it comes to drug pricing and rebate reform – and the CEO was notably optimistic about US policy changes that could impact the pharmaceutical industry.

Read said he expects drug rebates will be eliminated under public health insurance plans in a policy shift that will spill over to the private sector

More from Drug Pricing

More from Scrip

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.